Antimicrobial resistance (AMR) represents a major global threat across human, animal, plant food and environmental sectors, threatening the effective treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fung...i, resulting in prolonged illness and increased mortality, often felt hardest by the most vulnerable populations. AMR also endangers the sustainability of agri-food systems and food safety.
Since 2010 there is a strong commitment from FAO, OIE and PAHO to fight AMR, working together to mitigate the risks in the interconnection among the human health, animal health and the environment. In this context, the organizations now joined forces in the implementation of the project ‘Working Together to Fight Antimicrobial Resistance’ to ensure a coherent “One Health” approach recognizing the multidimensionality and necessity of an intersectoral response that is needed to address the problem of AMR.
The overall strategic objective of the three-year project (2020-22) supported and financed by the European Union (EU) is to contribute to tackle AMR through the implementation of National AMR Action Plans by working with seven Latin American partner countries: Argentina, Brazil, Chile, Colombia, Paraguay, Peru and Uruguay.
more
Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and ...parasites no longer respond to these medicines, rendering them ineffective and making infections more difficult to treat. This resistance increases the risk of disease spread, severe illness, disability, and death. Although AMR is a natural phenomenon driven by genetic
changes in pathogens, it is significantly accelerated by human activities such as the misuse and overuse of antimicrobials in healthcare, agriculture, and animal husbandry.
more
n light of the potential risk posed by SARS-CoV-2 variants, in January 2021 WHO organized an ad hoc consultation to discuss the development of an R&D agenda in response to existing and emerging SARS-CoV-2 variants.
The key objectives were to identify the critical research questions related to var...iants and agree on a research approach to address them. Six breakout groups covered a range of specific issues related to COVID-19 variants: Epidemiology and mathematical modelling; evolutionary biology; animal models; assays and diagnostics; clinical management and therapeutics; and vaccines.
This report is a summary of presentations and panel discussions.
more
What do we know about Omicron variant so far? WHO's Dr Maria Van Kerkhove updates on the transmissibility, severity, symptoms and ways to protect yourself in Science in 5.
If Omicron is less severe, why are people ending up in the hospital and dying from it? Is it true that everyone will eventually get Omicron? Why is it important to reduce transmission? WHO's Dr Maria Van Kerkhove explains in Science in 5.
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).
The outbreak of the coronavirus is leading to increased challenges in clinical management and uncertainty among the general population. To support the advice and treatment of patients, we have updated our Knowledge Library to include an informative Learning Card about COVID-19.
This update contai...ns essential details, as well as references to reputable sources and the newest treatment recommendations from the institutes and authorities who are evaluating these developments on a daily basis. The Learning Card has been written, curated and extensively checked by our qualified team of international physicians.
more
Guideline zu folgenden Themen:
I. Hintergrund
II. Mögliche Anpassung der Empfehlungen für Kontaktpersonen unter medizinischem Personal an Situationen mit relevantem Personalmangel
III. Ergänzende Grundsätze der medizinischen Versorgung in der aktuellen Situation
Outline
• Welcome and objectives
• Microbiology, epidemiology and clinical presentation
• Surveillance for imported cases including case definitions
• Laboratory diagnosis • Infection prevention and hospital readiness
• Patient flow and actions required at each step
• Co-ord...inating a public health response
more
BMJ 2020;368:m800 doi: 10.1136/bmj.m800 (Published 5 March 2020)
Проект от 3 февраля 2020 г.
Эпидемиологические данные свидетельствуют о том, что 2019-нКоВ может передаваться от человека к человеку. Во время предшествующих вспышек, ...вызванных коронавирусами, в том числе коронавирусом ближневосточного респираторного синдрома (БВРС-КоВ) и коронавиру- сом тяжелого острого респираторного синдрома (ТОРС-КоВ), передача от человека к человеку чаще всего происходила капельным путем, при личном контакте и через зараженные предме- ты. Способы передачи 2019-нКоВ, по всей вероятности, те же.
more
Проект – 24 января 2020 г.
WHO/2019-nCoV/Readiness/v2020.2
Временные рекомендации
7 марта 2020 г.
Чрезвычайно важно задействовать механизмы координа- ции как можно раньше – задолго до начала широкого распространения инфе...кции внутри местных сообществ. Необходимо пересмотреть существующие националь- ные планы обеспечения готовности и системы управле- ния инцидентами в области общественного здравоохранения, интегрировав в них общегосудар- ственный подход и принцип участия всего общества. Не- смотря на то, что заболевание COVID-19 отличается от гриппа, существующий план обеспечения готовности к пандемии гриппа будет уместной отправной точкой.
more